Kancera AB (publ)

Stockholm Stock Exchange KAN.ST

Kancera AB (publ) EBITDA for the year ending December 31, 2023: USD -6.11 M

Kancera AB (publ) EBITDA is USD -6.11 M for the year ending December 31, 2023, a -22.99% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Kancera AB (publ) EBITDA for the year ending December 31, 2022 was USD -4.97 M, a 0.53% change year over year.
Kancera AB (publ) EBITDA for the year ending December 31, 2021 was USD -4.99 M, a 7.97% change year over year.
Kancera AB (publ) EBITDA for the year ending December 31, 2020 was USD -5.43 M, a -52.64% change year over year.
Kancera AB (publ) EBITDA for the year ending December 31, 2019 was USD -3.55 M, a 30.43% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Stockholm Stock Exchange: KAN.ST

Kancera AB (publ)

CEO	Mr. Peter Selin
IPO Date	Feb. 25, 2011
Location	Sweden
Headquarters	Karolinska Institutet Science Park
Employees	5
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.

Key trends

Past 5 years